<DOC>
	<DOCNO>NCT01829035</DOCNO>
	<brief_summary>This randomize , multi-center , open-labeled , phase III study patient advance HCC . A total 338 patient randomize ( 1:1 ) one two treatment arm , receive sorafenib ( Arm Combination-treatment ; Arm C ) without ( Arm Sorafenib alone treatment ; Arm S ) cTACE . All patient initially give sorafenib within 72 hour randomization . Treatment continue criterion treatment discontinuation meet . After treatment period , patient undergo follow survival every 12 week ( ±7 day ) last dose , survival follow perform least 1.5 year last patient 's last treatment .</brief_summary>
	<brief_title>A Randomized , Controlled Phase III Trial Sorafenib With Without cTACE Patients With Advanced HCC</brief_title>
	<detailed_description>The superiority Arm C ( cTACE+Sorafenib ) Arm S ( Sorafenib ) OS period verify ITT set FAS use stratified log-rank test . Stratification factor consist mUICC stage ( III vs. IV ) , Vascular invasion ( none Vp1-2 vs. Vp3-4 presence ) , Child-Pugh score ( 5 vs. 6-7 ) , serum AFP level ( ≥200 ng/mL vs. &lt; 200 ng/mL ) . The significance level 5 % ( one-sided ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>To eligible participate study , patient must meet following criterion : 1 . Signed write informed consent 2 . Clinical histological diagnosis HCC base guideline Korean Liver Cancer Study Group National Cancer Center Korea 3 . At least one typical enhance index lesion liver bidimensionally measurable multiphasic spiral CT scan dynamic contrastenhanced MRI , size large tumor 15 cm less enrollment . 4 . Tumor condition confirm abdominal imaging ( contrast enhance CT ± MRI ) chest imaging ( CT ) perform within 4 week prior treatment initiation : 5 . Age least 20 year . 6 . ECOG Performance Status 0 , 1 2 . 7 . ChildPugh class A B ( ChildPugh score ≤ 7 ) . 8 . Life expectancy least 16 week . 9 . Adequate bone marrow , liver , renal function assess follow laboratory requirement ( transfusion , restoration ) , conduct within 14 day prior screen : 10 . Female patient least 1 year postmenopausal , surgically sterile childbearing potential must negative urine pregnancy test within 14 day prior first treatment , use least one medically acceptable effective contraceptive method last 2 month prior Screening Visit : method effective contraception result low failure rate ( i.e . le 1 % per year ) use consistently correctly barrier method ( implant , injectable contraceptive , oral contraceptive , intrauterine contraceptive device ) , hormonal IUD , sexual abstinence vasectomize partner .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TACE</keyword>
	<keyword>Sorafenib</keyword>
</DOC>